20 results on '"Idelalisib -- Research"'
Search Results
2. Research from University of Iowa Broadens Understanding of Leukemia (PI3Kd Inhibition Potentiates Glucocorticoids in B-lymphoblastic Leukemia by Decreasing Receptor Phosphorylation and Enhancing Gene Regulation)
3. Studies in the Area of Biology Reported from University of Cologne (Functional Impact and Molecular Binding Modes of Drugs That Target the Pi3k Isoform P110 Delta)
4. Research Results from University of Cologne Update Knowledge of Biology (Functional impact and molecular binding modes of drugs that target the PI3K isoform p110d)
5. Research from Rostock University Medical Center Has Provided New Data on Apoptosis (Combined BCL-2 and PI3K/AKT Pathway Inhibition in * * KMT2A* * -Rearranged Acute B-Lymphoblastic Leukemia Cells)
6. City of Hope National Medical Center Details Findings in Chronic Lymphocytic Leukemia (Current Status of Phosphoinotiside-3 Kinase Inhibitors In Blood Cancers)
7. Findings on Pharmacology Reported by Investigators at University of South China [Development of Pi3k Inhibitors: Advances In Clinical Trials and New Strategies (Review)]
8. Humboldt University Berlin Researchers Provide New Insights into Pharmaceutical Research (Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes)
9. Findings from Harvard Medical School Yields New Findings on Chronic Lymphocytic Leukemia (Activation of the Mapk Pathway Mediates Resistance To Pi3k Inhibitors In Chronic Lymphocytic Leukemia)
10. New Anticancer Agents Study Results Reported from Southwest Medical University (Pi3k/akt/mtor Signaling As Targets for Developing Anticancer Agents From Marine Organisms)
11. New Findings from University of Santiago Describe Advances in Vascular Diseases and Conditions (The Pi3k Delta Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential)
12. Research from Center for Research Provides New Data on Vascular Diseases and Conditions (The PI3Kd Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential)
13. New Kinase Inhibitors Data Have Been Reported by Researchers at Ludwig-Maximilians-University Munich (The PI3K -Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression)
14. Findings from University of Ljubljana Has Provided New Information about Chronic Lymphocytic Leukemia (EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia ...)
15. Study Data from Jean-Marie Michot et al Provide New Insights into B-Cell Lymphoma (Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?)
16. Findings on Follicular Lymphoma Described by Researchers at Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS) (PI3Kd inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of ...)
17. Research from Rostock University Medical Center in Cancer Research Provides New Insights (Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that ...)
18. Findings from University of Southern Florida Broaden Understanding of Kinase Inhibitors (The Dual Pi3k Delta/ck1 Epsilon Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects On Cll T Cells)
19. Findings from Johns Hopkins University School of Medicine Broaden Understanding of Colitis (A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal ...)
20. Recent Findings in Chronic Lymphocytic Leukemia Described by Researchers from Laval University (Ugt2b17 Modifies Drug Response In Chronic Lymphocytic Leukaemia)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.